Özet:

Objective: Transcatheter aortic valve implantation (TAVI), which is an actual treatment method for advanced aortic stenosis (AS) in high-risk patients, has been applied to many patients in our clinic. This study aimed to show whether the mortality and morbidity results of the TAVI procedure performed in our clinic were similar to those in the literature. Methods: Patients who underwent TAVI for severe AS between April 2012 and February 2019 were evaluated. Society of Thoracic Surgeons scores were calculated. Biochemical parameters before and after the procedure and change in echocardiographic parameters after the procedure were determined. Results: The mean age of the patients was 78 (62-89) years and 56.82% (n=25) were female. The average mean gradient of the patients before and after the procedure were 42 (20-72) and 10 (0-26) mmHg, respectively (p<0.001). In-hospital mortality rate was 9.09% (n=4), peri-procedural mortality rate was 15.9% (n=7). There was only one record of death in TAVI procedures performed after 2015. The Edwards Sapien valve was implanted in 50% (n=22) of patients, while Portico, Corevalve and Evolute valves were implanted in 25% (n=11), 18.18% (n=8) and 6.81% (n=3) of patients, respectively. Thirty (68.18%) patients had TAVI implantation without balloon pre-dilatation. There was no difference in peri-procedural mortality between patients who had and had not balloon pre-dilatation (n=2, 6.7%, and n=2, 14.3%; p=0.581, respectively). Two patients showed moderate aortic regurgitation after valve implantation. Eight patients had stage 1 acute kidney failure (AKF), whereas one patient had stage 2 AKF. One patient required permanent pacemaker implantation because of complete heart block. Conclusion: When the studies in the literature were examined, the relatively high mortality rates were observed when TAVI procedure was first used. The number of deaths in our clinic has decreased significantly over the years, in accordance with the literature.

Anahtar Kelimeler: